erythromycin has been researched along with ethidium bromide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Elkins, CA; Mullis, LB | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Beceiro, A; Bou, G; Canle, D; Fernández, A; Lasa, I; Latasa, C; Mallo, S; Molina, F; Pérez, A; Pérez, S; Poza, M; Tomás, Mdel M; Villanueva, R | 1 |
| Arpin, C; Fournier, M; Gagné, S; Hernould, M; Quentin, C | 1 |
| Adler, B; Al-Hasani, K; Boyce, J; Dunstone, M; Hatfaludi, T | 1 |
| Kamal, N; Shafer, WM | 1 |
| Elkins, CA; Jung, CM; Lacher, DW; Mullis, LB | 1 |
| Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
| Floyd, JL; Floyd, JT; Kumar, SH; Smith, KP; Varela, MF | 1 |
| Barreca, ML; Cannalire, R; Cecchetti, V; Couto, I; Felicetti, T; Machado, D; Manfroni, G; Massari, S; Sabatini, S; Santos Costa, S; Tabarrini, O; Viveiros, M | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Bora, A; Deka, B; Devi, MV; Dihingia, A; Pahari, P; Sarma, S; Sen, T; Singh, AK; Suri, M | 1 |
13 other study(ies) available for erythromycin and ethidium bromide
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Binding, Competitive; Carrier Proteins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Indicators and Reagents; Microbial Sensitivity Tests; Progesterone; Steroids | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
Topics: Bacterial Proteins; Base Sequence; beta-Lactamases; Carrier Proteins; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Genes, MDR; Genetic Vectors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins | 2007 |
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
Topics: Aeromonas hydrophila; Anti-Bacterial Agents; Bacterial Proteins; Biological Transport, Active; Dipeptides; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA; Substrate Specificity | 2008 |
Characterization of TolC efflux pump proteins from Pasteurella multocida.
Topics: Amino Acid Sequence; Animals; Bacterial Outer Membrane Proteins; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Membrane Transport Proteins; Mutation; Pasteurella multocida; Phylogeny | 2008 |
Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Escherichia coli; Escherichia coli Proteins; Genetic Complementation Test; Hemolysin Proteins; Humans; Microbial Sensitivity Tests; Neisseria meningitidis | 2010 |
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
Topics: Animals; Anti-Bacterial Agents; Catfishes; Cattle; Disease Reservoirs; Escherichia coli; Escherichia coli Proteins; Feces; Gene Expression Regulation, Bacterial; Intestines; Mice; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Mutation; Phylogeny; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Rats; Recombination, Genetic; Sequence Analysis, DNA; Structure-Activity Relationship | 2010 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
Topics: Amino Acid Sequence; Bacterial Proteins; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Ethidium; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Onium Compounds; Organophosphorus Compounds; Phylogeny; Sequence Homology, Amino Acid; Sodium Dodecyl Sulfate; Staphylococcus aureus; Trimethoprim; Vancomycin | 2010 |
Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
Topics: Anti-Bacterial Agents; Drug Design; Genistein; Mycobacterium avium; Quinolones | 2017 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Potentiating the intracellular killing of Staphylococcus aureus by dihydroquinazoline analogues as NorA efflux pump inhibitor.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cell Survival; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Multidrug Resistance-Associated Proteins; Quinazolines; Staphylococcus aureus; Structure-Activity Relationship; THP-1 Cells | 2022 |